Skip to main content

Advertisement

Table 2 Completed targeted therapy clinical trials in ES-SCLC

From: Emerging therapies for small cell lung cancer

Phase Study Treatment arms Patients (n) ORR (%) PFS (months) OS (months)
First line
 II ECOG-ACRIN 2511 Veliparib + etoposide + cisplatin vs. placebo + etoposide + cisplatin 128 71.9 vs. 65.6 (P = 0.57) 6.1 vs. 5.5 (HR = 0.75; P = 0.06) 10.3 vs. 8.9 (HR = 0.83; P = 0.17)
Relapsed
 II NCT01638546 Veliparib + temozolomide vs.placebo + temozolomide 104 39 vs. 14 (P = 0.016) 3.8 vs. 2.0 (P = 0.39) 8.2 vs. 7.0 (P = 0.50)
 II NCT02454972 Lurbinectedin (PM01183) 68 39.3 4.1 11.8
 II TRINITY Rovalpituzumab tesirine 177 16 4.1a 5.6
 II ALTER 1202 Anlotinib vs. placebo 120 71.6 vs. 13.2b 4.1 vs. 0.7 (HR = 0.19; P < 0.0001) 7.3 vs. 4.9 (HR = 0.53; P = 0.0210, not yet mature)
  1. aDOR duration of response
  2. bDCR disease control rate